Hypertrophic obstructive cardiomyopathy (HOCM) affects approximately 1 in 500 people globally. The condition results in hypertrophy of the interventricular septum and thickening of the left ventricular wall. Surgical management to resect the thickened myocardium or septal alcohol ablation are currently considered the mainstay treatment option for HOCM refractory to pharmacological therapy. In this special report we aim to highlight the current landscape of septal mass reduction in HOCM. Next, we describe the evolving discipline of minimally invasive techniques for reducing outflow tract obstruction in patients with HOCM. We further consider future options and outline a possible percutaneous approach for septal myectomy with a novel device.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Hensley N, Dietrich J, Nyhan D, Mitter N, Yee M, Brady M. Hypertrophic cardiomyopathy. Anesth. Analg. 120(3), 554–569 (2015).
MedlineGoogle Scholar
2. Ommen SR, Mital S, Burke MA et al. 2020 AHA/ACC guideline of the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 76(25), e159–e240 (2020). • Comprehensive guidance from the American Heart Association regarding diagnosis and treatment of hypertrophic obstructive cardiomyopathy.
MedlineGoogle Scholar
3. Spertus JA, Fine JT, Elliott P et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase III trial. Lancet 397(10293), 2467–2475 (2021).
Medline CASGoogle Scholar
4. Wu JJ, Seco M, Medi C et al. Surgery for hypertrophic cardiomyopathy. Biophys. Rev. 7(1), 117–125 (2015).
MedlineGoogle Scholar
5. Kotkar KD, Said SM, Schaff HV. Transapical approach for myectomy in hypertrophic cardiomyopathy. Ann. Cardiothorac. Surg. 6(4), 419–422 (2017).
MedlineGoogle Scholar
6. Arévalos V, Rodríguez-Arias JJ, Brugaletta S et al. Alcohol septal ablation: an option on the rise in hypertrophic obstructive cardiomyopathy. J. Clin. Med. 10(11), 2276 (2021).
MedlineGoogle Scholar
7. Spirito P, Rossi J, Maron BJ. Alcohol septal ablation: in which patients and why? Ann. Cardiothorac. Surg. 6(4), 369–375 (2017).
MedlineGoogle Scholar
8. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 58, e212–e260 (2011).
Medline CASGoogle Scholar
9. Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter. Cardiovasc. Interv. 88(1), 107–115 (2016).
MedlineGoogle Scholar
10. Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. (11), 896–905 (2015).
MedlineGoogle Scholar
11. Bytyçi I, Nistri S, Mörner S, Henein MY. Alcohol septal ablation versus septal myectomy treatment of obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. J. Clin. Med. 9(10), 3062 (2020).
MedlineGoogle Scholar
12. Panaich SS, Badheka AO, Chothani A et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998–2010]). Am. J. Cardiol. 114(9), 1390–1395 (2014).
MedlineGoogle Scholar
13. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J. Interv. Cardiol. 19(4), 319–27 (2006).
MedlineGoogle Scholar
14. El Masry H, Breall JA. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr. Cardiol. Rev. 4(3), 193–197 (2008).
MedlineGoogle Scholar
15. Kim LK, Swaminathan RV, Looser P et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011. JAMA Cardiol. 1(3), 324–332 (2016).
MedlineGoogle Scholar
16. Gilmanov D, Bevilacqua S, Solinas M et al. Minimally invasive septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy and intrinsic mitral valve disease. Innovations (Phila.) 10(2), 106–113 (2015)
MedlineGoogle Scholar
17. Musharbash FN, Schill MR, Henn MC, Damiano RJ Jr. Minimally invasive septal myectomy for hypertrophic obstructive cardiomyopathy. Innovations (Phila.) 12(6), 489–492 (2017).
MedlineGoogle Scholar
18. Musharbash FN, Schill MR, Hansalia VH et al. Minimally invasive versus full-sternotomy septal myectomy for hypertrophic cardiomyopathy. Innovations (Phila.) 13(4), 261–266 (2018).
MedlineGoogle Scholar
19. Fang J, Wang R, Liu H et al. Transapical septal myectomy in the beating heart via a minimally invasive approach: a feasibility study in swine. Interact. Cardiovasc. Thorac. Surg. 30(2), 303–311 (2020). •• Comprehensive overview with illustrations of septal myectomy using a novel resection device.
MedlineGoogle Scholar
20. Liu L, Zhou M, Zuo L et al. Echocardiography Guided Liwen Procedure™ for the treatment of obstructive hypertrophic cardiomyopathy in a patient with prior aortic valve replacement surgery: liwen procedure for intra-myocardial radiofrequency ablation. Echocardiography 35(8), 1230–1232 (2018).
MedlineGoogle Scholar
21. Liu L, Li J, Zuo L et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 72(16), 1898–1909 (2018).
MedlineGoogle Scholar
22. Zhou M, Ta S, Hahn RT et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol. 7(5), 529–538 (2022).
MedlineGoogle Scholar
23. Rogers JH, Franzen O. Percutaneous edge-to-edge MitraClip therapy in the management of mitral regurgitation. Eur. Heart J. 32(19), 2350–2357 (2011).
MedlineGoogle Scholar
24. Sherif MA, Paranskaya L, Yuecel S et al. MitraClip step by step; how to simplify the procedure. Neth. Heart J. 25(2), 125–130 (2017).
Medline CASGoogle Scholar
25. Sorajja P, Pedersen WA, Bae R et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 67(24), 2811–2818 (2016).
MedlineGoogle Scholar
26. Schäfer U, Frerker C, Thielsen T et al. Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip. EuroIntervention 11(8), 942–7 (2015).
MedlineGoogle Scholar
27. Thomas F, Rader F, Siegel RJ. The use of mitraclip for symptomatic patients with hypertrophic obstructive cardiomyopathy. Cardiology 137(1), 58–61 (2017).
MedlineGoogle Scholar
28. Patel V. Method and device for the treatment of hypertrophic cardiomyopathy. US 8,906,052 B1 (2014). •• Comprehensive outline of the steps and techniques involved in septal mass reducing using our novel device.
Google Scholar

Vol. 19, No. 4

Metrics

Downloaded 58 times

History

Received 28 September 2022

Accepted 15 May 2023

Published online 30 June 2023

Published in print March 2023

Information

Keywords

Author contributions

V Patel, M Parikh and U Ojha were equally involved in conception, drafting, and editing this manuscript. All authors gave final approval of the manuscript and agree to be accountable for all aspects of the work.

Acknowledgments

Illustrations were created using the image library from https://smart.servier.com/ and https://biorender.com/ - no specific permission is required at the time of publication.

Financial & competing interests disclosure

V Patel is the inventor of the novel myectomy device described in the manuscript and holds a patent on the product. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download